AR053973A1 - Procedimiento de obtencion de una piridin-amida. - Google Patents
Procedimiento de obtencion de una piridin-amida.Info
- Publication number
- AR053973A1 AR053973A1 ARP050104020A ARP050104020A AR053973A1 AR 053973 A1 AR053973 A1 AR 053973A1 AR P050104020 A ARP050104020 A AR P050104020A AR P050104020 A ARP050104020 A AR P050104020A AR 053973 A1 AR053973 A1 AR 053973A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- degree
- amida
- pyridin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- NBJZEUQTGLSUOB-UHFFFAOYSA-N 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC=C1Cl NBJZEUQTGLSUOB-UHFFFAOYSA-N 0.000 abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 2
- 239000012948 isocyanate Substances 0.000 abstract 1
- 150000002513 isocyanates Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000002798 polar solvent Substances 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Developing Agents For Electrophotography (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Reivindicacion 1:Un procedimiento para preparar el compuesto de formula (1) que comprende, en una primera etapa, hacer reaccionar el compuesto de formula (5) con isocianato de 4-cloro-3-trifluorometilfenilo en un disolvente orgánico no clorado, inerte hacia isocianatos, inicialmente cargando el compuesto de formula (5) a una temperatura de entre 20 degree C y 60 degree C y mezclando con isocianato de 4-cloro-3-trifluorometilfenilo de tal forma que la temperatura de reaccion no exceda de 70 degree C proporcionando el compuesto de formula (2) y, en una segunda etapa, mezclando el compuesto de formula (2) con ácido p-toluensulfonico en un disolvente polar a una temperatura de reaccion de entre 40 degree C hasta la temperatura de reflujo del disolvente usado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04023131 | 2004-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053973A1 true AR053973A1 (es) | 2007-05-30 |
Family
ID=35457568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104020A AR053973A1 (es) | 2004-09-29 | 2005-09-26 | Procedimiento de obtencion de una piridin-amida. |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8124782B2 (es) |
| EP (1) | EP1797037B1 (es) |
| JP (2) | JP2008514657A (es) |
| KR (1) | KR101263032B1 (es) |
| CN (1) | CN101052619B (es) |
| AR (1) | AR053973A1 (es) |
| AU (1) | AU2005289099B2 (es) |
| BR (1) | BRPI0515944B1 (es) |
| CA (1) | CA2581835C (es) |
| CU (1) | CU23754B7 (es) |
| CY (1) | CY1116126T1 (es) |
| DK (1) | DK1797037T3 (es) |
| DO (1) | DOP2005000183A (es) |
| EC (1) | ECSP077357A (es) |
| ES (1) | ES2532377T3 (es) |
| GT (1) | GT200500269A (es) |
| HN (1) | HN2005000768A (es) |
| HR (1) | HRP20150295T1 (es) |
| IL (1) | IL182046A0 (es) |
| MA (1) | MA28883B1 (es) |
| MY (1) | MY149873A (es) |
| NO (1) | NO339647B1 (es) |
| NZ (1) | NZ554119A (es) |
| PE (5) | PE20091585A1 (es) |
| PL (1) | PL1797037T3 (es) |
| PT (1) | PT1797037E (es) |
| SG (1) | SG155997A1 (es) |
| SI (1) | SI1797037T1 (es) |
| SV (1) | SV2006002243A (es) |
| TW (1) | TWI382973B (es) |
| UA (1) | UA90691C2 (es) |
| UY (1) | UY29143A1 (es) |
| WO (1) | WO2006034796A1 (es) |
| ZA (1) | ZA200702511B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| ES2288694T3 (es) | 2003-05-20 | 2008-01-16 | Bayer Pharmaceuticals Corporation | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. |
| KR101139557B1 (ko) | 2003-07-23 | 2012-04-30 | 바이엘 파마슈티칼스 코포레이션 | 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아 |
| EP1797038B1 (en) * | 2004-09-29 | 2012-06-13 | Bayer Pharma Aktiengesellschaft | Thermodynamically stable form of bay 43-9006 tosylate |
| BRPI0515944B1 (pt) | 2004-09-29 | 2021-11-09 | Bayer Healthcare Llc | Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida |
| EP1868579B1 (en) | 2005-03-07 | 2010-09-29 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| JP2010509382A (ja) * | 2006-11-14 | 2010-03-25 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ |
| KR101553211B1 (ko) * | 2007-09-10 | 2015-09-15 | 씨아이피엘에이 엘티디. | Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체 |
| WO2009054004A2 (en) * | 2007-10-22 | 2009-04-30 | Natco Pharma Limited | Process for the preparation of sorafenib |
| US8217061B2 (en) | 2008-01-17 | 2012-07-10 | Sicor Inc. | Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof |
| EP2142507A1 (en) * | 2008-03-06 | 2010-01-13 | Sicor, Inc. | Process for the preparation of sorafenib and salts thereof |
| CN103254126A (zh) * | 2008-09-19 | 2013-08-21 | 苏州泽璟生物制药有限公司 | 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物 |
| AU2010299484A1 (en) | 2009-09-24 | 2012-05-03 | Ranbaxy Laboratories Limited | Polymorphs of sorafenib acid addition salts |
| AU2010299483B2 (en) * | 2009-09-24 | 2014-08-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of sorafenib tosylate |
| US8552197B2 (en) * | 2009-11-12 | 2013-10-08 | Ranbaxy Laboratories Limited | Sorafenib ethylsulfonate salt, process for preparation and use |
| WO2011076711A2 (en) | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide |
| CA2788146C (en) | 2010-01-29 | 2014-11-25 | Ranbaxy Laboratories Limited | Sorafenib dimethtyl sulphoxide solvate |
| CN102190616B (zh) * | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| CN102617458A (zh) * | 2010-05-18 | 2012-08-01 | 张南 | 抗癌用化合物的制备方法 |
| JP2013531067A (ja) | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
| AU2011310532B2 (en) | 2010-10-01 | 2016-01-14 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
| WO2012071425A1 (en) | 2010-11-22 | 2012-05-31 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sorafenib besylate, and processes for preparations thereof |
| EP2559431A1 (en) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide |
| CN103664771B (zh) * | 2012-09-19 | 2016-03-30 | 齐鲁制药有限公司 | 索拉非尼的晶型a及其制备方法 |
| WO2014118807A1 (en) * | 2013-02-04 | 2014-08-07 | Intas Pharmaceuticals Limited | A novel process for the preparation of sorafenib tosylate form iii |
| CN104710354A (zh) * | 2013-12-13 | 2015-06-17 | 江苏豪森药业股份有限公司 | 高纯度索拉非尼的制备方法 |
| CN104761492A (zh) * | 2014-01-03 | 2015-07-08 | 正大天晴药业集团股份有限公司 | 对甲苯磺酸索拉非尼的晶型及其制备方法 |
| CN104177292A (zh) * | 2014-08-08 | 2014-12-03 | 亿腾药业（泰州）有限公司 | 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法 |
| CN110204483B (zh) * | 2014-12-01 | 2021-06-29 | 石药集团中奇制药技术（石家庄）有限公司 | 一种甲苯磺酸索拉非尼新晶型及其制备方法 |
| EP3109236B1 (en) | 2015-06-23 | 2017-08-09 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii |
| CN105181844A (zh) * | 2015-09-11 | 2015-12-23 | 江苏嘉逸医药有限公司 | 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法 |
| CN105585523A (zh) * | 2015-12-29 | 2016-05-18 | 上海北卡医药技术有限公司 | 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途 |
| CN107840823B (zh) * | 2016-09-20 | 2021-08-17 | 意大利合成制造有限公司 | 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法 |
| CN107915676A (zh) * | 2017-10-26 | 2018-04-17 | 魏海霞 | 索拉非尼的制备方法 |
| CN109796400B (zh) * | 2017-11-16 | 2022-07-29 | 四川科伦药物研究院有限公司 | 一种甲苯磺酸索拉菲尼晶型及其制备方法 |
| CN113773249A (zh) * | 2020-06-10 | 2021-12-10 | 杭州中美华东制药有限公司 | 索拉非尼游离碱晶型Form X及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU86960A1 (fr) * | 1987-07-31 | 1989-03-08 | Oreal | Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux |
| JPH02934A (ja) * | 1988-05-27 | 1990-01-05 | Konica Corp | 非線形光学材料 |
| JP2971291B2 (ja) * | 1993-06-02 | 1999-11-02 | 田辺製薬株式会社 | 光学活性２−アミノ酪酸の製法 |
| JP3866323B2 (ja) * | 1996-03-27 | 2007-01-10 | ポーラ化成工業株式会社 | 新規ｎ−ベンジルベンズアミド誘導体 |
| JPH09316069A (ja) * | 1996-03-28 | 1997-12-09 | Ajinomoto Co Inc | 新規キサントン誘導体 |
| PL215029B1 (pl) * | 1999-01-13 | 2013-10-31 | Bayer Corp | Omega-karboksyarylopodstawione difenylomoczniki jako inhibitory kinazy raf oraz ich zastosowanie |
| WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| GB2367816A (en) * | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
| WO2003047579A1 (en) * | 2001-12-03 | 2003-06-12 | Bayer Pharmaceuticals Corporation | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| DE10203086A1 (de) * | 2002-01-28 | 2003-07-31 | Bayer Ag | 5-Ring Heterozyklen |
| EP1478358B1 (en) * | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| AU2003255424A1 (en) * | 2002-08-13 | 2004-03-03 | Sandoz Ag | A cefdinir intermediate |
| DK1559715T3 (da) * | 2002-10-21 | 2007-12-27 | Kirin Brewery | N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form |
| ES2288694T3 (es) * | 2003-05-20 | 2008-01-16 | Bayer Pharmaceuticals Corporation | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. |
| BRPI0515944B1 (pt) | 2004-09-29 | 2021-11-09 | Bayer Healthcare Llc | Processo para a preparação de 4-{4-[({[4-cloro-3-(trifluorometil)fe-nil]amino}carbonil) amino]fenóxi}nmetilpiridina-2-carboxamida |
-
2005
- 2005-09-20 BR BRPI0515944-0A patent/BRPI0515944B1/pt active IP Right Grant
- 2005-09-20 PT PT05794785T patent/PT1797037E/pt unknown
- 2005-09-20 DK DK05794785T patent/DK1797037T3/en active
- 2005-09-20 SG SG200906449-4A patent/SG155997A1/en unknown
- 2005-09-20 AU AU2005289099A patent/AU2005289099B2/en not_active Ceased
- 2005-09-20 UA UAA200704750A patent/UA90691C2/ru unknown
- 2005-09-20 WO PCT/EP2005/010118 patent/WO2006034796A1/en not_active Ceased
- 2005-09-20 NZ NZ554119A patent/NZ554119A/en not_active IP Right Cessation
- 2005-09-20 SI SI200531947T patent/SI1797037T1/sl unknown
- 2005-09-20 KR KR1020077009652A patent/KR101263032B1/ko not_active Expired - Lifetime
- 2005-09-20 CN CN2005800373684A patent/CN101052619B/zh not_active Expired - Lifetime
- 2005-09-20 EP EP05794785.5A patent/EP1797037B1/en not_active Expired - Lifetime
- 2005-09-20 CA CA2581835A patent/CA2581835C/en not_active Expired - Lifetime
- 2005-09-20 JP JP2007533904A patent/JP2008514657A/ja active Pending
- 2005-09-20 PL PL05794785T patent/PL1797037T3/pl unknown
- 2005-09-20 HR HRP20150295TT patent/HRP20150295T1/hr unknown
- 2005-09-20 US US11/664,332 patent/US8124782B2/en active Active
- 2005-09-20 ES ES05794785.5T patent/ES2532377T3/es not_active Expired - Lifetime
- 2005-09-23 DO DO2005000183A patent/DOP2005000183A/es unknown
- 2005-09-26 AR ARP050104020A patent/AR053973A1/es active IP Right Grant
- 2005-09-27 MY MYPI20054553A patent/MY149873A/en unknown
- 2005-09-28 PE PE2009000510A patent/PE20091585A1/es active IP Right Grant
- 2005-09-28 TW TW094133620A patent/TWI382973B/zh not_active IP Right Cessation
- 2005-09-28 GT GT200500269A patent/GT200500269A/es unknown
- 2005-09-28 PE PE2009000509A patent/PE20091584A1/es active IP Right Grant
- 2005-09-28 UY UY29143A patent/UY29143A1/es not_active IP Right Cessation
- 2005-09-28 PE PE2005001144A patent/PE20060825A1/es active IP Right Grant
- 2005-09-28 PE PE2009000512A patent/PE20091587A1/es active IP Right Grant
- 2005-09-28 PE PE2009000511A patent/PE20091586A1/es not_active Application Discontinuation
- 2005-09-29 SV SV2005002243A patent/SV2006002243A/es active IP Right Grant
- 2005-10-04 HN HN2005000768A patent/HN2005000768A/es unknown
-
2007
- 2007-03-20 IL IL182046A patent/IL182046A0/en active IP Right Grant
- 2007-03-26 CU CU20070069A patent/CU23754B7/es active IP Right Grant
- 2007-03-27 ZA ZA200702511A patent/ZA200702511B/en unknown
- 2007-03-28 EC EC2007007357A patent/ECSP077357A/es unknown
- 2007-03-30 MA MA29788A patent/MA28883B1/fr unknown
- 2007-04-26 NO NO20072173A patent/NO339647B1/no unknown
-
2012
- 2012-11-02 JP JP2012242831A patent/JP5583190B2/ja not_active Expired - Lifetime
-
2015
- 2015-03-17 CY CY20151100268T patent/CY1116126T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053973A1 (es) | Procedimiento de obtencion de una piridin-amida. | |
| PE20070103A1 (es) | Procesos para la preparacion de compuestos de 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona | |
| PE20091582A1 (es) | Procedimiento para la preparacion de dihidropteridinonas | |
| ES8204428A1 (es) | Procedimiento para preparar alfa-aril-1h-1,2,4-triazol-1- etanoles | |
| PE20100716A1 (es) | Proceso para la sintesis de 1-bromo-3-nitro-5-trifluorometil-benceno | |
| ECSP099529A (es) | Inhibidores de cinasa mapk/erk | |
| ECSP066406A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| SV2004001373A (es) | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares. ref. pcs22051 | |
| WO2007001803A3 (en) | Cure catalyst, composition, electronic device and associated method | |
| ATE440094T1 (de) | Fumagillolderivate und verfahren zu deren herstellung | |
| ATE496078T1 (de) | Aufgesäuerte polyesterpolyurethan-dispersionen | |
| CL2012000374A1 (es) | Metodo para la preparacion de una composicion saborizante activa que comprende una primera reaccion entre un compuesto amino y un carbonilo, resultando una primera mezcla de intermediarios, una segunda reaccion con un segundo compuesto amino solo o en combinacion con un compuesto carbinilo, resultando una segunda mezcla de intermediarios, reacciones serparadas adicionales con compuestos de otras clases quimicas, ultima reaccion que comprende una mezcla de todas las mezclas de intermediarios anteriores. | |
| AR065775A1 (es) | Procedimiento para preparar 2,6-dicloro-4-(trifluorometil)-fenilhidracina usando mezclas de dicloro-fluoro-trifluorometilbencenos | |
| NO20062515L (no) | Faststoffpreparat som omfatter en insulinsensibilisator, en insulinsekretagog og en polyoksyetylensorbitanfettsyreester | |
| ZA201003751B (en) | Process for the synthesis of propargylated aminoindan derivatives | |
| ES2129736T3 (es) | Procedimiento en continuo para la fabricacion de isocianatos organicos. | |
| YU52303A (sh) | Postupak karbamoilacije alkohola | |
| ECSP045291A (es) | Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas | |
| ATE406349T1 (de) | Herstellung von astaxanthin | |
| CL2008002563A1 (es) | Procedimiento para preparar los compuestos intermediarios derivados de acetoglucometilenos que comprende reaccionar un compuesto derivado de acetoglucocetonas con un disolvente organico | |
| BR0315671A (pt) | Processo para a preparação de um composto | |
| ES2568927T3 (es) | Proceso para fabricar derivados de adamantano con alto rendimiento | |
| AR044329A1 (es) | Proceso de sintesis de modafinil | |
| BRPI0519582A2 (pt) | mÉtodo para melhorar a estabilidade de um derivado de aÇécar nço fluoretado, formulaÇço de um derivado de aÇécar nço fluoretado, e, cassete para um aparelho automatizado para sÍntese | |
| ES2532886T3 (es) | Producción de carbamatos en un recipiente usando catalizadores sólidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |